Using EEG to Predict Depression Treatment Response to rTMS in Patients With Major Depression

Baptist Health South Florida

Status: Withdrawn

Conditions: Major Depression; Repetitive Transcranial Magnetic Stimulation

Treatments: Diagnostic Test: Electroencephalogram (EEG)

Study type: Observational

Funder types: Other

Identifiers

NCT04575285

TMS Depression

Details and patient eligibility

About

Repetitive Transcranial Magnetic Stimulation (rTMS) is a promising, novel, non-invasive therapy for depression. The study is looking at changes in specific electroencephalogram parameters in depressed patients treated with rTMS can serve as predictors of depression treatment response among cancer patents undergoing rTMS treatment of depression.

Full description

The study will be a prospective, single arm trial in which a set of patients who will be treated for major depression using Repetitive Transcranial Magnetic Stimulation (according to FDA approved rTMS standard care practices) also will undergo EEG recording before Repetitive Transcranial Magnetic Stimulation treatment begins, and at the completion of treatment. The Hamilton Depression Rating Scale will be given to participants by the neuropsychiatrist at baseline and weekly intervals till the completion of treatment.

The neuropsychiatrist investigators expect to see about 12 patients per year who meet treatment criteria for Repetitive Transcranial Magnetic Stimulation. Therefore, it is expected to recruit 24 subjects into the research study over a two-year period.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed with cancer
• Comorbid diagnosis of major depressive disorder
• Age ≥ 18 years
• Baseline Hamilton Depression Rating Scale (HDRS) score ≥ 18
• Failed one or more adequate antidepressant trials (including selective serotonin reuptake inhibitors or SSRIs, selective norepinephrine reuptake inhibitors or SNRIs, tricyclic antidepressants or TCAs). A failed treatment response may be due to lack of antidepressant efficacy or intolerable side effects.

Exclusion criteria

• History of seizure or epilepsy
• History of concussion
• History of bipolar disorder
• Comorbid psychotic disorder
• Primary brain tumor or metastasis to brain
• Active comorbid substance use disorder
• History or current diagnosis of dementia
• Current pregnancy
• Unable to attend regular treatment sessions
• Any other condition in which a physician investigator feels may subject the participant to undue risk

Trial design

0 participants in 1 patient group

Electroencephalogram (EEG)

Description:

All participants will undergo EEG recording at baseline and end of treatment for a duration of 10-20 minutes per session.

Treatment:

Diagnostic Test: Electroencephalogram (EEG)